Translational Research Working Group developmental pathway for immune response modifiers

Martin A. Cheever, Jeffrey Schlom, Louis M. Weiner, H. Kim Lyerly, Mary L. Disis, Addison Greenwood, Oren Grad, William G. Nelson

Research output: Contribution to journalReview articlepeer-review

28 Scopus citations


TheTranslational Research Working Group (TRWG) was created as a national initiative to evaluate the current status of the investment of National Cancer Institute in translational research and envision its future. TheTranslational Research Working Group conceptualized translational research as a set of six developmental processes or pathways focused on various clinical goals. One of those pathways describes the development of immune response modifiers such as vaccines and cytokines. A hallmark of the Immune Response Modifier Developmental Pathway is the coordinated development of multiple components. The Immune Response Modifier Pathway was conceived not as a comprehensive description of the corresponding real-world processes but rather as a tool designed to facilitate movement of a candidate assay through the translational process to the point where it can be handed off for definitive clinical testing. This paper discusses key challenges associated with the immune response modifier agent development process in light of the pathway.

Original languageEnglish (US)
Pages (from-to)5692-5699
Number of pages8
JournalClinical Cancer Research
Issue number18
StatePublished - Sep 15 2008

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Translational Research Working Group developmental pathway for immune response modifiers'. Together they form a unique fingerprint.

Cite this